Patient characteristics.
Parameter | N (%) |
---|---|
Age at lenalidomide initiation (yr) | |
Median (range) | 66 (46–83) |
Sex | |
Male | 8 (25.8) |
Female | 23 (74.2) |
Time from initial MDS diagnosis to lenalidomide initiation (wk) | |
Median | 56 |
Range | 0–424 |
Transfusion dependence | |
At MDS diagnosis | 23 (74.2) |
At lenalidomide initiation | 31 (100) |
Karyotype | |
Isolated del(5q) only | 28 (90.3) |
+1 additional abnormality | 3 (9.7) |
WHO classification | |
MDS with isolate del(5q) | 27 (87.1) |
MDS, multilineage dysplasia | 2 (6.5) |
MDS, excess blast-1 | 1 (3.2) |
MDS, unclassifiable | 1 (3.2) |
International Prognosis Scoring System (IPSS) | |
Low | 16 (51.6) |
Intermediate-1 | 15 (48.4) |
Intermediate-2 or high | 0 (0%) |
IPSS-revised (IPSS-R) | |
Very low | 2 (6.5) |
Low | 16 (51.6) |
Intermediate | 15 (41.9) |
High/very high | 0 (0) |
Abbreviaion: MDS, myelodysplastic syndrome.